ProductsBack/ELISA Kit for Anterior Gradient 2 (AGR2)

ELISA Kit for Anterior Gradient 2 (AGR2)

Name: ELISA Kit for Anterior Gradient 2 (AGR2)
SKU: SEC285HU_U80
Availability: BackOrder

SEC285HU

Product group Assays

Overview

Supplier
Cloud-Clone Corp.
Product Name
ELISA Kit for Anterior Gradient 2 (AGR2)
Delivery Days Customer
12
Assay Detection Range
1.56-100ng/mL
Assay Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anterior Gradient 2 (AGR2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and ...
Assay Sensitivity
The minimum detectable dose of this kit is typically less than 0.55ng/mL
Assay Test Principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Anterior Gradient 2 (AGR2). Standards or samples are then added to the appropriate ...
Assay Time
3h
Certification
Research Use Only
UNSPSC
41116158

Maarouf A, Boissard A, Henry C, et al. Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy‑induced senescence escape. Int J Oncol. 2022,60(1):pii: 5. doi: 10.3892/ijo.2021.5295.
Read this paper
Garri C, Howell S, Tiemann K, et al. Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 2018,9(44):27363-27379. doi: 10.18632/oncotarget.25221
Read this paper
Garczyk S, von Stillfried S, Antonopoulos W, et al. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection. PLoS One. 2015,10(4):e0122106. doi: 10.1371/journal.pone.0122106
Read this paper
Chan A, Prassas I, Dimitromanolakis A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 2014,20(22):5787-95. doi: 10.1158/1078-0432.CCR-14-0289
Read this paper
Makawita S, Dimitromanolakis A, Soosaipillai A, et al. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer. 2013,13:404. doi: 10.1186/1471-2407-13-404
Read this paper
Kani K, Malihi PD, Jiang Y, et al. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013,73(3):306-15. doi: 10.1002/pros.22569
Read this paper